Overview
CAR-T cells have been validated effective in treating CD19 positive B cell lymphoma. Other lymphomas like Hodgkin's lymphoma and anaplastic large cell lymphoma are CD30 positive. In this study, a newly CD30 targeted CART therapy ICAR30 is designed to specifically kill those CD30 expressing malignancies including Hodgkin's lymphoma and CD30+ anaplastic large cell lymphoma. The subjects will receive several doses of autologous ICAR30 T cells infusion and then the safety, treating effects and lasting period of these cells in vivo will be evaluated.
Eligibility
Inclusion Criteria:
Hodgkin's lymphoma, anaplastic large cell lymphoma and other CD30 positive malignancies,
relapsed or refractory:
- Karnofsky or Lansky score >50;
- Expected survival>12 weeks;
- Hgb > 8.0;
- FEV1, FVC and DLCO ≥50% of expected corrected for hemoglobin;
- LVEF≥50%;
- Creatinine<2.5mg/dl;
- Bilirubin<2.5mg/dl;
- ALT (alanine aminotransferase)/AST (aspartate aminotransferase)<3 fold normal;
- Patients must sign an informed consent.
Exclusion Criteria:
- Pregnant or lactating;
- Uncontrolled active infection including hepatitis B or C;
- HIV positive;
- Active clinically significant CNS dysfunction;
- Current use of systemic steroids;
- Heterogenous lymphocyte treatments within recent 6 months;